Idelalisib Plus Rituximab Versus Ibrutinib in the Treatment of Relapsed/refractory Chronic Lymphocytic Leukaemia: A Real-World Analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)

Martin Spacek,Lukas Smolej,Martin Simkovic,Lucie Nekvindova,Zlatuse Kristkova,Yvona Brychtova,Anna Panovska,Stanislava Maslejova,Lucie Bezdekova,Dominika Ecsiova,Pavel Vodarek,Jana Zuchnicka,Jana Mihalyova,Renata Urbanova,Peter Turcsanyi,Daniel Lysak,Jan Novak,Martin Brejcha,Tereza Likarova,Prokop Vodicka,Jana Baranova,Marek Trneny,Michael Doubek

British journal of haematology（2023）

引用 1|浏览45
暂无评分
关键词
chronic lymphocytic leukaemia,ibrutinib,idelalisib,real-world evidence,rituximab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要